245 related articles for article (PubMed ID: 16291013)
1. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B.
Stein EA; Sniderman A; Laskarzewski P
Am J Cardiol; 2005 Nov; 96(9A):36K-43K; discussion 34K-35K. PubMed ID: 16291013
[TBL] [Abstract][Full Text] [Related]
2. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
3. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
Miller M; Ginsberg HN; Schaefer EJ
Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
[TBL] [Abstract][Full Text] [Related]
4. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
5. Strategies for optimizing lipid management.
Ballantyne CM
Postgrad Med; 2004 Sep; 116(3 Suppl):13-20. PubMed ID: 19667671
[TBL] [Abstract][Full Text] [Related]
6. Advanced lipoprotein testing: recommendations based on current evidence.
Lau JF; Smith DA
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):1-31. PubMed ID: 19217510
[TBL] [Abstract][Full Text] [Related]
7. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
[TBL] [Abstract][Full Text] [Related]
8. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
9. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
10. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.
Maki KC; Galant R; Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):59K-64K; discussion 34K-35K. PubMed ID: 16291016
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
[TBL] [Abstract][Full Text] [Related]
12. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
13. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
Sachdeva A; Cannon CP; Deedwania PC; Labresh KA; Smith SC; Dai D; Hernandez A; Fonarow GC
Am Heart J; 2009 Jan; 157(1):111-117.e2. PubMed ID: 19081406
[TBL] [Abstract][Full Text] [Related]
14. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
15. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
Ayyobi AF; McGladdery SH; McNeely MJ; Austin MA; Motulsky AG; Brunzell JD
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1289-94. PubMed ID: 12750118
[TBL] [Abstract][Full Text] [Related]
16. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients.
Boumaiza I; Omezzine A; Rejeb J; Rebhi L; Kalboussi N; Ben Rejeb N; Nabli N; Ben Abdelaziz A; Boughazala E; Bouslama A
Metab Syndr Relat Disord; 2010 Dec; 8(6):515-22. PubMed ID: 20715933
[TBL] [Abstract][Full Text] [Related]
18. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
Ballantyne CM
Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein B level in patients with type 2 diabetes who achieved goal of low density lipoprotein cholesterol and non-high density lipoprotein cholesterol.
Sathavarodom N; Boonyavarakul A
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S166-72. PubMed ID: 21280530
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.
St-Pierre AC; Cantin B; Dagenais GR; Després JP; Lamarche B
Am J Cardiol; 2006 Apr; 97(7):997-1001. PubMed ID: 16563904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
